



**eLITERATURE
REVIEW**

eMedicalDermatology Review

Presented by
The Johns Hopkins University
School of Medicine, The Institute
for Johns Hopkins Nursing and the
University of Tennessee College
of Pharmacy

Supported by an Educational Grant
from Centocor, Inc.

POST TEST & EVALUATION

June 2007 Edition - ACPE Program #064-999-07-251-H01

Please Complete the Post Test and Evaluation and Mail/Fax to:

THE UNIVERSITY OF TENNESSEE

**Health Science Center
College of Pharmacy
213 Conference Center
600 Henley Street
Knoxville, TN 37996**

Tel: (865) 974-6605
Fax: (865) 974-2987

A statement of CE credit will be mailed within 4 weeks
of successful completion and evaluation of the program

Name _____

Address: _____

City: _____

State: _____ Zip: _____

Phone Number: _____

License Number: _____

POST TEST

Post Test Question 1

Antibodies to IL-12/23 have been shown to result in which ONE of the following?

Answer Choices for Question 1

- A. the development of positive antinuclear antibodies.
- B. psoriasis-like eruptions.
- C. dose-related improvement in PASI scores.
- D. marked increase in infection.
- E. marked increase in malignancies.

Question #1 Correct Answer & Commentary

- C. 52%-81% of patients treated with IL-12/23 achieved PASI 75 in dose-related increments.

Post Test Question 2

Infliximab therapy is commonly associated with the development of which ONE of the following?

Answer Choices for Question 2

- A. anti-ENA antibodies.
- B. anti-IgG double-stranded DNA antibodies.
- C. anti-IgM double-stranded DNA antibodies.
- D. anti-centrimere antibodies.
- E. anti-cardiolipin antibodies.

Question #2 Correct Answer & Commentary

- C. The majority of patients who develop antinuclear antibodies as a result of infliximab therapy also have anti-IgM double-stranded DNA antibodies.

Post Test Question 3

Which ONE of the following MOST ACCURATELY completes this statement:
“Infliximab therapy ____?”

Answer Choices for Question 3

- A. is often effective for psoriasis, when other treatments have failed.
- B. commonly causes lupus.
- C. commonly causes psoriasis.
- D. commonly causes malignancy.
- E. commonly causes infection.

Question #3 Correct Answer & Commentary

- A. Even patients who have failed multiple systemic therapies respond to infliximab infusions.

Post Test Question 4

Characteristics of TNF-associated psoriasis typically include which ONE of the following?

Answer Choices for Question 4

- A. onset within days of starting TNF inhibitors.
- B. development of psoriatic arthritis in all cases.
- C. erythroderma.
- D. response to UVB phototherapy.
- E. involvement of palms and soles.

Question #4 Correct Answer & Commentary

- E. Palms, soles, and pubic involvement occur in multiple case reports of patients with TNF inhibitor-induced psoriasis.

Post Test Question 5

Which ONE of the following statements is TRUE about patients switching from one TNF blocker to another for rheumatoid arthritis?

Answer Choices for Question 5

- A. Patients who fail therapy with one TNF blocker usually fail with another.
- B. Side effects that occur with one TNF blocker usually occur with another.
- C. Patients who discontinue one TNF blocker because of lack of efficacy usually discontinue a second TNF blocker for lack of efficacy.
- D. Patients who discontinue one TNF blocker for side effects usually discontinue a second TNF blocker for side effects.
- E. The majority of patients who switch from one TNF blocker to a second are still under therapy six months after switching.

Question #5 Correct Answer & Commentary

- E. Patients with rheumatoid arthritis failing one TNF blocker may respond well to a different TNF blocker.

Post Test Question 6

Which ONE of the following most accurately completes this statement: “The meta-analysis studying serious infections and malignancies in patients treated with TNF inhibitors _____”?

Answer Choices for Question 6

- A. included only patients in clinical trials for rheumatoid arthritis.
- B. adjusted risk for duration of exposure.
- C. included data for all three TNF inhibitors.
- D. compared the frequency of malignancies to those in established databases such as SEER.
- E. demonstrated a dose-related increase in infections.

Question #6 Correct Answer & Commentary

- A. The meta-analysis published in JAMA only studied patients in rheumatoid arthritis clinical trials.

EVALUATION

Evaluation Question 1

This program met my overall objectives.

	A. Strongly Agree
	B. Somewhat Agree
	C. Neutral
	D. Somewhat Disagree
	E. Strongly Disagree

Evaluation Question 2

This program explains the new biologic therapies recently introduced or in development for psoriasis.

	A. Strongly Agree
	B. Somewhat Agree
	C. Neutral
	D. Somewhat Disagree
	E. Strongly Disagree

Evaluation Question 3

This program describes the current evidence concerning the side effects of specific biologic agents.

	A. Strongly Agree
	B. Somewhat Agree
	C. Neutral
	D. Somewhat Disagree
	E. Strongly Disagree

Evaluation Question 4

This program details clinical outcomes occurring when switching patients from one biologic agent to another.

	A. Strongly Agree
	B. Somewhat Agree
	C. Neutral
	D. Somewhat Disagree
	E. Strongly Disagree

Evaluation Question 5

What is your overall opinion of this program as it applies to your clinical practice?

	A. Very useful
	B. Somewhat useful
	C. Neutral
	D. Not very useful
	E. Not at all useful

Evaluation Question 6

In what way(s) can this program be improved?

Evaluation Question 7

CME activities must be "free of commercial bias for or against any product." In this regard, did you perceive any commercial influence in this web-based presentation?

	A. Yes (please explain)
--	-------------------------

<input type="checkbox"/>	B. No
--------------------------	-------

Evaluation Question 8

Did the author(s) disclose discussion of off-label drugs and/or devices?

<input type="checkbox"/>	A. Yes
--------------------------	--------

<input type="checkbox"/>	B. No (please explain)
--------------------------	------------------------

<input type="checkbox"/>	C. N/A - There was no discussion of off-label drugs and/or devices
--------------------------	--------------------------------------------------------------------

Evaluation Question 9

Would you like to receive information on other CME activities?

<input type="checkbox"/>	A. Yes - my email is:
--------------------------	-----------------------

<input type="checkbox"/>	B. No, thanks
--------------------------	---------------

Evaluation Question 10

Enter the number of hours it took you to complete this course (e.g., 0.5, 1.25, etc.):
